New trial: treating actinic keratosis with HPV vaccines
The VAXAK Trial at Bispebjerg Hospital marks the first step in applying a commercially available HPV vaccine to treat actinic keratosis (AK). AK is the most common premalignant skin disease in Denmark.
The research project is spearheaded by Dr. Emily Wenande and Professor Merete Hædersdal in collaboration with the Danish Cancer Society. The group expects to share the first results in the year to come.
Danish Research Center for Skin Cancer is currently recruiting individuals with sun-damaged skin for the VAXAK trial.
Want to take part in a clinical trial?
Clinical studies are vital for developing better treatment options for people with skin cancer. For this reason, our research center periodically recruits individuals who wish to participate in our trials.
We recruit healthy individuals as well as individuals with skin cancer or sun damage.
If you wish to learn more about upcoming studies and what it means to participate in one, please visit this page. Your help can make a real difference.
